Update on Oral Therapy for Psoriasis
Purpose of Review
The aim of this review article is to summarize the information of oral treatments of psoriasis, with emphasis in new information and newer drugs.
Methotrexate has an adequate efficacy and safety profile with low cost and large real-life evidence. Cyclosporine’s therapeutic power is abated by the long-term safety issues. Acitretin has a niche in special circumstances such as combination with phototherapy, HIV population, or special forms of psoriasis such as palmoplantar, pustular, and erythrodermic psoriasis. Apremilast, the newer available drug of this group demonstrates a modest but acceptable efficacy and good safety in this population. Other drugs have been evaluated with different results in this field.
Oral therapy for psoriasis is widely used in patients with moderate to severe disease; thus, it is crucial to know the latest information and indications as well as the recent development of new drugs.
KeywordsMethotrexate Cyclosporine Acitretin Apremilast Psoriasis
Compliance with Ethical Standards
Conflict of Interest
Dr. Fernando Valenzuela declares consultancy for Pfizer, Novartis, and Janssen; expert testimony for Novartis, AbbVie, and Deutschepharma; and payment for development of educational presentations including service on sopeakers’ bureaus for Novartis, AbbVie, and Deutschepharma.
Drs. Javier Fernández and Pablo Santa María declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as • Of importance •• Of major importance
- 3.Gooderham M. Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis. Skin Ther Lett. 2013;18(7):1–4.Google Scholar
- 5.•• Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris—update 2015—short version—EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol: JEADV. 2015;29(12):2277–94. A recent evidence-based guidelines mandatory to psoriasis involved physicians. https://doi.org/10.1111/jdv.13354.CrossRefPubMedGoogle Scholar
- 6.Menting SP, Dekker PM, Limpens J, Hooft L, Spuls PI. Methotrexate dosing regimen for plaque-type psoriasis: a systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation. Acta Derm Venereol. 2016;96(1):23–8. https://doi.org/10.2340/00015555-2081.CrossRefPubMedGoogle Scholar
- 7.•• West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials. PloS one. 2016;11(5):e0153740. Important information regarding methotrexate previous evidence. https://doi.org/10.1371/journal.pone.0153740.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Kragballe K, Jansen CT, Geiger JM, Bjerke JR, Falk ES, Gip L, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Actadermato-venereologica. 1989;69:35–40.Google Scholar
- 15.Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85. https://doi.org/10.1016/j.jaad.2009.03.027.CrossRefPubMedGoogle Scholar
- 16.• Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49. Pivotal study on apremilast and its use in psoriasis. CrossRefPubMedGoogle Scholar
- 17.Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–99. https://doi.org/10.1111/bjd.14164.CrossRefPubMedGoogle Scholar
- 18.•• Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann-Theis D, Ghoreschi K, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:528–37. This study provides a well designed evidence on the use of subcutaneous methotrexate in moderate to severe plaque psoriasis CrossRefPubMedGoogle Scholar
- 21.• Otero ME, van den Reek JM, Seyger MM, van de Kerkhof PC, Kievit W, de Jong EM. Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE. Br J Dermatol. 2017;177:497–504. Relevant real life data in patients using methotrexate. CrossRefPubMedGoogle Scholar
- 24.Colombo D, Banfi G, Cassano N, Graziottin A, Vena GA, Fiori GG, et al. The GENDER ATTENTION Observational Study: gender and hormonal status differences in the incidence of adverse events during cyclosporine treatment in psoriatic patients. Adv Ther. 2017;34(6):1349–63. https://doi.org/10.1007/s12325-017-0526-7.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.• Davila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gomez-Garcia FJ, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol: JEADV. 2016;30:1942–50. Extensive real life evidence of Spanish psoriatic population and their treatment. PubMedGoogle Scholar
- 26.• Belinchon I, Ramos JM, Carretero G, Ferrandiz C, Rivera R, Dauden E, et al. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. J Eur Acad Dermatol Venereol : JEADV. 2017;31:1700–8. Another report of Spanish registry in psoriasis. CrossRefPubMedGoogle Scholar
- 27.Lee MS, Chang CH, Lin RY, Lai MS. Risks of hypertension associated with cyclosporine, nonsteroidal anti-inflammatory drugs, and systemic glucocorticoids in patients with psoriasis: a nationwide population-based nested case-control study in Taiwan. Pharmacoepidemiol Drug Saf. 2016;25(2):133–40. https://doi.org/10.1002/pds.3890.CrossRefPubMedGoogle Scholar
- 29.Bauer R, Schutz R, Orfanos CE. Impaired motility and random migration of vital polymorphonuclears in vitro after therapy with oral aromatic retinoid in psoriasis. Int J Dermatol. 1984;23(1):72–7. https://doi.org/10.1111/j.1365-4362.1984.tb05670.x.CrossRefPubMedGoogle Scholar
- 35.White SI, Marks JM, Shuster S. Etretinate in pustular psoriasis of palms and soles. Br J Dermatol. 1985;113(5):581–5. https://doi.org/10.1111/j.1365-2133.1985.tb02382.x.CrossRefPubMedGoogle Scholar
- 37.Ozawa A, Ohkido M, Haruki Y, Kobayashi H, Ohkawara A, Ohno Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol. 1999;26(3):141–9. https://doi.org/10.1111/j.1346-8138.1999.tb03444.x.CrossRefPubMedGoogle Scholar
- 39.Reich K SJ, Day R, et al. Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials. Poster. Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20–24; San Francisco, CA.Google Scholar
- 42.Xeljanz [package insert].New York, NY: Pfizer Laboratories; 2015.Google Scholar
- 45.Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–77. https://doi.org/10.1111/j.1365-2133.2012.11168.x.CrossRefPubMedGoogle Scholar
- 46.• Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet (London, England). 2015;386:552–61. First phase III study showing a non inferiority assessment of a small molecule compared to a biologic in psoriasis. CrossRefGoogle Scholar
- 47.Valenzuela F, Bissonnette R, Bakos N, TsaiT-F, Harper MK, Ports WC, et al. Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long-term efficacy and safety up to 54 months in an open-label extension study. In: Program and abstracts, 26th EADV Congress; 13–17 September 2017, Geneva, Switzerland.Google Scholar
- 48.Langley R CA, Foley P, et al. Safety of tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: integrated data analysis from the global clinical trials. In: Program and abstracts, 73rd Annual Meeting of the American Academy of Dermatology; March 20, 2015; San Francisco, CA.Google Scholar
- 49.US Food and Drug Administration. Arthritis Advisory Committee Meeting. NDA 203214: tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had inadequate response to one or more disease-modifying anti-rheumatic drugs. May 9, 2012.Google Scholar
- 50.Pfizer receives complete response letter from FDA for oral XELJANZ® (tofacitinib citrate) supplemental new drug application for moderate to severe chronic plaque psoriasis [press release]. New York, NY: Pfizer Inc. October 14, 2015.Google Scholar
- 51.Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137–45. https://doi.org/10.1111/bjd.12266.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Concert pharmaceuticals Inc. Deuterated derivatives of ruxolitinib WO2013188783A1. 2013.Google Scholar
- 55.Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–76. https://doi.org/10.1111/bjd.14403.CrossRefPubMedGoogle Scholar
- 57.Papp K, Pariser D, Catlin M, Wierz G, Ball G, Akinlade B, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015;173(3):767–76. https://doi.org/10.1111/bjd.13745.CrossRefPubMedGoogle Scholar
- 58.Can-Fite Biopharma Ltd. Pharmaceutical composition comprising a3 adenosine receptor agonist (ib-meca/cf-101) for treatment of psoriasis. WO2011027348A1. 2011.Google Scholar
- 60.David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol : JEADV. 2012;26(3):361–7. https://doi.org/10.1111/j.1468-3083.2011.04078.x.CrossRefPubMedGoogle Scholar